Gastrointestinal Tumors最新文献

{"title":"Investigation of Novel Urinary Biomarkers in Hepatocellular Carcinoma Risk in a Predominantly African American Population: A Case-Control Study.","authors":"Alexandra Shingina, Xijing Han, Lei Fan, Harvey Murff, Robert Coffey, Ginger L Milne, Qi Dai, Martha Shrubsole","doi":"10.1159/000538131","DOIUrl":"10.1159/000538131","url":null,"abstract":"<p><strong>Introduction: </strong>African Americans are at increased risk of hepatocellular carcinoma (HCC) compared to other racial and ethnic groups. We investigated the associations of four urinary biomarkers of prostaglandin E₂ (PGE-M), prostacyclin (PGI-M), and thromboxane (11dTxB₂) synthesis and the ratio of PGI-M to 11dTXB₂ with HCC risk in a cohort of predominantly African American populations.</p><p><strong>Methods: </strong>We conducted a nested case-control study (50 cases; 43 with HCC, 151 controls) in the Southern Community Cohort Study (SCCS), a large prospective cohort study including over 80,000 study participants, of whom two-thirds are African Americans. Urine samples were collected at enrollment and subsequently analyzed to assess biomarker levels. Multivariable regression models adjusted for age, race, sex, BMI, smoking status, NSAID use, education level, income, and alcohol consumption were used to assess the relationship between the biomarker and HCC risk.</p><p><strong>Results: </strong>Only 11dTxB₂ (OR = 11.50; 95% CI [2.34-56.47] for highest tertile vs. lowest tertile, <i>p</i> = 0.004) and the PGI-M/11dTXB₂ ratio of the second quartile (0.25-0.49) (OR = 5.16; 95% CI [1.44-18.47]; <i>p</i> = 0.01) were significantly associated with increased risk of liver cancer.</p><p><strong>Conclusion: </strong>11dTXB₂ and PGI-M/11dTXB₂ ratio may be urinary markers of HCC risk, particularly among African Americans, and future prospective studies are needed to evaluate this finding further and to develop accessible methods.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"10 1","pages":"29-37"},"PeriodicalIF":0.8,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of FLOT versus CROSS Regimens for Patients with Oesophagogastric Cancers.","authors":"Adel Shahnam,&nbsp;Udit Nindra,&nbsp;Nicholas McNamee,&nbsp;Robert Yoon,&nbsp;Ray Asghari,&nbsp;Weng Ng,&nbsp;Deme Karikios,&nbsp;Mark Wong","doi":"10.1159/000531536","DOIUrl":"10.1159/000531536","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment of oesophageal (OC), gastro-oesophageal junction (GOJ), and gastric cancer (GC) includes either neoadjuvant Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) for OC or GOJ or perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for OC, GOJ, and GC adenocarcinomas. This study aims to describe the real-world outcomes of patients with GC, GOJ, and OC treated with FLOT or CROSS and identify variables associated with efficacy through exploratory analysis. We also aimed to evaluate the comparison of FLOT and CROSS for the treatment of OC and GOJ adenocarcinomas.</p><p><strong>Methods: </strong>This is a retrospective observational study of patients with locally advanced OC, GOJ, or GC treated with FLOT or CROSS between January 2015 and June 2021 in 5 cancer centres across Sydney, Australia. Long-rank test was used to compare survival estimated between subgroups. Hazard ratios for univariate and multivariate analyses were estimated with Cox proportional regression.</p><p><strong>Results: </strong>The study included 168 patients. The 24-month relapse-free survival (RFS) and overall survival (OS) for FLOT were 59% and 69%, respectively. The median RFS was 29.6 months and median OS was not reached. For CROSS, the 24-month RFS and OS were 55% and 63% with a median RFS and OS of 28.5 and 40.2 months, respectively. There was no difference in OS and RFS between the treatments. FLOT was less tolerable than CROSS with more dose reductions, treatment discontinuation, and clinically relevant grade 3 and 4 toxicity. Neutrophil lymphocyte ratio was associated with survival for both treatments.</p><p><strong>Conclusion: </strong>Similar efficacy outcomes were seen in this real-world population compared to the clinical trials for FLOT and CROSS.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"1 1","pages":"19-28"},"PeriodicalIF":1.6,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65304354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Serum Zinc Levels and Clinicopathological Characteristics in Patients with Gastric Cancer.","authors":"Tsutomu Namikawa,&nbsp;Masato Utsunomiya,&nbsp;Keiichiro Yokota,&nbsp;Masaya Munekage,&nbsp;Sunao Uemura,&nbsp;Hiromichi Maeda,&nbsp;Hiroyuki Kitagawa,&nbsp;Michiya Kobayashi,&nbsp;Kazuhiro Hanazaki","doi":"10.1159/000529707","DOIUrl":"https://doi.org/10.1159/000529707","url":null,"abstract":"<p><strong>Introduction: </strong>Although it was reported that serum zinc levels were lower in patients with various malignancies, serum zinc levels of patients with gastric cancer were not well documented.</p><p><strong>Objectives: </strong>This study aimed to evaluate the association between clinicopathologic features and serum zinc levels in preoperative patients with gastric cancer.</p><p><strong>Methods: </strong>The study enrolled 83 patients scheduled for gastric cancer surgery at the Kochi Medical School. Clinical data were obtained to investigate associations between clinicopathological features, including nutritional indicators and serum zinc levels. Serum zinc deficiency was defined as serum zinc level <80 μg/dL.</p><p><strong>Results: </strong>The median zinc level of the 83 patients was 73 μg/dL (range, 20-152 μg/dL), and serum zinc deficiency was present in 66.3% of patients. Albumin was significantly lower in the zinc low level group than in the normal group (3.9 g/dL vs. 4.4 g/dL, <i>p</i> < 0.001), and the median serum zinc level was significantly lower in the albumin <4.1 g/dL group than in the albumin ≥4.1 g/dL group (69 μg/dL vs. 82 μg/dL, <i>p</i> < 0.001). Lymphocyte count was significantly lower in the zinc low level group than in the normal group (1,500 vs. 1810 years, <i>p</i> = 0.041). The median serum zinc level was significantly lower in the age ≥74 group than in the age <74 (71 μg/dL vs. 76 μg/dL, <i>p</i> = 0.002). Serum zinc levels showed a significant positive correlation with serum albumin (<i>r</i> = 0.637, <i>p</i> = 0.009).</p><p><strong>Conclusion: </strong>Serum zinc deficiency was found in 66.3% of preoperative patients with gastric cancer, which was highly correlated with serum albumin.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"10 1","pages":"6-13"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9276561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mixed Neuroendocrine and Non-Neuroendocrine Neoplasm of Pancreas: What Do We Know, What Have We Learnt?","authors":"Vijay W Dhakre,&nbsp;Sneha Tukaram Galande,&nbsp;Varsha Gunvant Patil,&nbsp;Nikita C Shah,&nbsp;Chetan Rathod,&nbsp;Kaiumarz S Sethna,&nbsp;Anjali D Amrapurkar","doi":"10.1159/000528759","DOIUrl":"https://doi.org/10.1159/000528759","url":null,"abstract":"<p><p>Pancreatic adeno-mixed neuroendocrine non-endocrine (pMINEN) tumors are extremely rare [Pancreatology. 2021;21(1):224-235]. They are known to have distal metastasis at presentation and have a comparatively lower survival rate than similar staged neuroendocrine (NEN) carcinoma, adenocarcinoma, and small-cell lung tumor from which its treatment patterns are extrapolated. Also, very less is known about its molecular structure and natural courses. There is a dearth of data about pMINEN in the literature, and also there is a lack of large multicentral trials due to which the MINEN tumors do not have a standard universal management protocol. We discuss here the clinical dilemmas that arise during diagnosis and reporting and urge to form a multicentric trial to formulate a focused protocolized approach. We describe here our encounter with a pancreatic head lesion which on immunohistochemical analysis turned out to be a pMINEN with moderately differentiating ductal adenocarcinoma and low-grade NEN tumor. Radical R0 surgery with multimodal treatment (chemotherapy + radiotherapy) gains improved survival in long term.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"10 1","pages":"14-18"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9711700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mast Cell Sarcoma of Small Intestine, Early Diagnosis, and Good Prognosis: An Extremely Rare Case Report and Review of the Literature.","authors":"Bita Geramizadeh,&nbsp;Sara Nabavizadeh,&nbsp;Alireza Rezvani,&nbsp;Nadereh Shamsolvaezin,&nbsp;Alireza Zahedinassab,&nbsp;Neda Khodadadi,&nbsp;Pouya Iranpour","doi":"10.1159/000528887","DOIUrl":"https://doi.org/10.1159/000528887","url":null,"abstract":"<p><p>Gastrointestinal mast cell sarcoma is a rare variant of mastocytosis. It is a unifocal tumor with high destructive capacity and metastatic potential. Diagnosis of mast cell sarcoma can be challenging and might be so delayed that unfavorable prognosis may be expected. In this case report, we will describe our experience with a case of mast cell sarcoma in the small intestine of an elderly woman, which was diagnosed early on throughout the course of her disease and successfully treated. The patient was a 59-year-old woman who presented with abdominal pain, flushing, weight loss, and vomiting. Imaging studies supported the existence of an infiltrative neoplasm in the jejunum. Then, surgical removal of the tumor was performed. The presence of mast cells in the resected tumor was confirmed by immunohistochemistry, histopathology, and Giemsa staining. After almost a year of follow-up, the patient's overall condition was fine, and no signs of recurrence were found. This is the first reported case of successfully treated gastrointestinal mast cell sarcoma. All of the previously reported cases had been diagnosed after recurrence with no response to treatment. Our case shows the significance of early diagnosis and treatment in this condition and its impact on outcome and prognosis. That could be achieved only if the pathologist has a high suspicion for this rare disease and keeps it in the back of one's mind.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"10 1","pages":"1-5"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/14/gat-2023-0010-0001-528887.PMC9892685.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10658900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing TCGA Data to Identify Gene Mutations Linked to Hepatocellular Carcinoma in Asians.","authors":"Tane Kim,&nbsp;Danny Issa,&nbsp;Mykola Onyshchenko","doi":"10.1159/000524576","DOIUrl":"https://doi.org/10.1159/000524576","url":null,"abstract":"<p><strong>Introduction: </strong>Liver cancer is the sixth most common and second most fatal type of cancer worldwide. Few treatment options are available as patients with liver cancer are often diagnosed in an advanced stage due to a lack of clinical symptoms. Effectively preventing and treating liver cancer relies heavily on early diagnosis; early diagnosis results from identifying and monitoring high-risk patients. Epigenetic risk factors, such as hepatitis B, hepatitis C, cirrhosis, nonalcoholic fatty liver disease, and alcohol/tobacco abuse, are highly prevalent in Asia and likely cause Asians to have a higher incidence and mortality rate of liver cancer. While these acquired risk factors are relatively well understood, the underlying genetic background of liver cancer in Asians has not been well established or correlated with clinical outcomes.</p><p><strong>Methods: </strong>In this study, we accessed The Cancer Genome Atlas (TCGA) hepatocellular carcinoma clinical and mutation data through TCGAbiolinksGUI.</p><p><strong>Results: </strong>We found that mutations in five genes (<i>TP53, TTN, OBSCN, MUC5B, CSMD1</i>) were statistically linked with increased mortality in Asians compared to non-Asians, four of which (<i>TTN, OBSCN, MUC5B, CSMD1</i>) were also more prevalent in the Asian population. Within the Asian cohort, two gene mutations (<i>TTN, HMCN1</i>) were statistically linked with worse outcomes. We also found that the <i>TP53</i> mutation predicts worse outcomes within the non-Asian cohort but not within the Asian cohort.</p><p><strong>Discussion/conclusion: </strong>Our findings can improve cancer care in the Asian population through better disease prognostication, evaluations for potential targeted therapy, and a deeper understanding of liver cancer pathogenesis.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"9 2-4","pages":"43-58"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/82/gat-0009-0043.PMC9801391.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10524479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Use of Direct Splenic Vein Anastomosis to the Interposition Internal Jugular Vein Graft after Extended Pancreatoduodenectomy to Avoid Sinistral Portal Hypertension.","authors":"Vijay W Dhakre,&nbsp;Shrikant S Suryawanshi,&nbsp;Vijay P Shewale,&nbsp;Chetan Rathod,&nbsp;Sneha Tukaram Galande,&nbsp;Kaiumarz S Sethna","doi":"10.1159/000522590","DOIUrl":"https://doi.org/10.1159/000522590","url":null,"abstract":"<p><p>Splenic vein (SV) ligation may be needed during portomesenteric junction resection, in pancreatoduodenectomy. Sinistral portal hypertension is a concern if the SV is not drained. Various techniques are described to reconstruct SV to avoid the variceal formation and sinistral portal hypertension which may lead to GI bleed. We describe a case of a 19-year-old female who underwent pancreatoduodenectomy for solid pseudopapillary neoplasm with portal-superior mesenteric vein junction resection and splenic venous was anastomosed into the interposition graft. We here share our unique experience of using an interposition internal jugular vein graft for a long venous defect and diverging morbidity of sinistral portal hypertension.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"9 2-4","pages":"69-73"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/b6/gat-0009-0069.PMC9801392.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10468134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of the Japan Esophageal Society Classification of Barrett's Esophagus for Diagnosing the Lateral Extent of Superficial Short-Segment Barrett's Esophageal Cancer.","authors":"Yugo Suzuki,&nbsp;Takayuki Okamura,&nbsp;Akira Matsui,&nbsp;Junnosuke Hayasaka,&nbsp;Kosuke Nomura,&nbsp;Daisuke Kikuchi,&nbsp;Shu Hoteya","doi":"10.1159/000525586","DOIUrl":"https://doi.org/10.1159/000525586","url":null,"abstract":"<p><strong>Introduction: </strong>The Japanese guidelines for endoscopic submucosal dissection (ESD) of Barrett's esophageal adenocarcinoma (BEA) recommend image-enhanced magnifying endoscopic examination for diagnosing the lateral extent of superficial esophageal adenocarcinoma. The Japan Esophageal Society Barrett's Esophagus (JES-BE) classification is proposed recently and is useful in terms of diagnostic accuracy. In this study, we retrospectively examined the usefulness of the JES-BE classification for differential diagnosis and determination of the extent of BEA originating in short-segment Barrett's esophagus.</p><p><strong>Methods: </strong>The study reviewed 51 lesions which underwent ESD for BEA. The circumference of the esophagogastric junction was divided into four parts, and the lesions were divided into those in the right anterior portion (RA group; <i>n</i> = 33) and those in other portions (non-RA group; <i>n</i> = 18). Clinicopathological characteristics and clinical outcomes were compared between the two groups.</p><p><strong>Results: </strong>JES-BE classification findings as \"dysplasia\" were seen in 48 out of 51 (94.1%) BEA lesions retrospectively. There was no significant difference in histological type, tumor depth, lymphovascular invasion, or the proportion of tumors with a positive or unknown horizontal or vertical margin status between the groups. The proportion of tumors with type 0-I morphology was significantly higher in the RA group (<i>p</i> = 0.023). The tumor size was significantly greater in the RA group (<i>p</i> = 0.034). According to the JES-BE classification, 31 lesions (93.9%) in the RA group and 17 lesions (94.4%) in the non-RA group were diagnosed as dysplasia. There was also no significant difference in the rate of consistency between the endoscopic and histopathological findings on the lateral extent of the lesion (90.9% vs. 83.3%; <i>p</i> = 0.612).</p><p><strong>Discussion/conclusions: </strong>The JES-BE classification may be useful for determining the extent of BEA.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"9 2-4","pages":"59-68"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/c5/gat-0009-0059.PMC9801400.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10468133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer: A Phase II Study (OGSG 1107)","authors":"Toshifumi Yamaguchi, M. Yoshida, H. Kawakami, T. Kii, H. Hasegawa, T. Miyamoto, T. Terazawa, Fukutaro Shimamoto, M. Yasui, D. Sakai, T. Shimokawa, Y. Kurokawa, M. Goto, T. Satoh","doi":"10.1159/000522610","DOIUrl":"https://doi.org/10.1159/000522610","url":null,"abstract":"Introduction: Previous prospective studies suggest that the sequential use of cytotoxic agents, such as oxaliplatin, in patients with metastatic colorectal cancer (mCRC) has the potential to improve prognosis and maintain quality of life than combination chemotherapy. The purpose of this study was to investigate the feasibility and effectiveness of a sequential treatment strategy consisting of an initial therapy (capecitabine, S-1, or 5-fluorouracil with leucovorin [LV/5-FU] plus bevacizumab) and subsequent therapy (i.e., initial therapy plus oxaliplatin) for mCRC. Methods: The primary endpoint was second progression-free survival (2nd PFS) between the start of initial therapy and tumor progression after sequential therapy; secondary endpoints were PFS after initial treatment, overall survival (OS), objective response rate (ORR), and safety. Results: Sixty-six patients were planned to be recruited. However, owing to a slow accrual rate, recruitment was terminated when only 19 patients were enrolled between 2011 and 2015; 4, 10, and 5 patients were administered capecitabine plus bevacizumab, S-1 plus bevacizumab, and LV/5-FU plus bevacizumab, respectively. The proportions of those with a KRAS status (wild-type/mutant/unknown) were 26%, 21%, and 53%, respectively. The median 2nd PFS and OS were 19.1 months and not reached, respectively. The ORR was 45.5% in the initial therapy and 16.7% in the subsequent therapy. Grade 3/4 toxicities included neutropenia (5%), proteinuria (5%), and hypertension (47%). Conclusion: Although our data are limited and preliminary, the sequential treatment strategy may provide a survival benefit in patients with mCRC. Further investigation of this treatment approach is warranted.","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"9 1","pages":"27 - 36"},"PeriodicalIF":1.6,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46958177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction over 32-Month Follow-Up","authors":"Davide Lanza, A. Casty, Stefan H. Schlosser","doi":"10.1159/000522363","DOIUrl":"https://doi.org/10.1159/000522363","url":null,"abstract":"Hilar cholangiocellular carcinoma (CCC) is a malignant neoplasm of epithelial origin occurring at the confluence of the right and left hepatic bile ducts. Typically, these tumors are small, poorly differentiated, exhibit aggressive biologic behavior with non-specific symptoms and tend to obstruct the intrahepatic bile ducts. Surgery is the only available curative option. Unfortunately, in less than half of the patients a complete resection is possible with poor survival rate in unresectable cases. In this report, we present the case of a 58-year-old woman with a history of unresectable hilar cholangiocarcinoma. Initially she was treated with intraductal dilatation of malignancy and placement of a plastic stent and chemotherapy (Gemcitabin® and Platinol®). Two years later she underwent a second-line chemotherapy with Gemcitabin® and Oxyplatin® because of tumor progression. Despite a second line chemotherapy and placement of an uncovered self-expandible metal stent (ucSEMS) that was extended later on by stent-in stent technique, there was tumor progression which led to a complex course with relapsing obstructive cholangiosepsis and cholestasis. Because of tumor ingrowth, endobiliary radiofrequency ablation of the malignant stenosis was performed in repeated sessions. This case illustrates that radiofrequency ablation of solitary malignant biliary obstruction is feasible, safe and allows an improvement of quality of life in non-operable patients.","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"9 1","pages":"12 - 18"},"PeriodicalIF":1.6,"publicationDate":"2022-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47824174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}